

Adenosine

CAUTION: High Administration Risk Rating	
Form	6mg per 2mL vial
Reconstitution	Already in solution
Compatibilty and Stability	N/A
Administration	IV Injection only Rapid IV bolus over 2 seconds either directly into central or large peripheral vein or into an IV line. If given into an IV line, it should be injected as close to the cannulation site as possible. Follow by a rapid sodium chloride 0.9% flush.
Monitoring & Adverse Drug Reactions	 Adenosine should only be used where facilities for cardiac monitoring and cardiorespiratory resuscitation equipment exist. The occurrence of angina, severe bradycardia, severe hypotension, respiratory failure, or asystole/cardiac arrest, should lead to immediate discontinuation of administration. Side effects are generally short lived as half-life is less than 10 seconds. They include facial flushing, shortness of breath, nausea, heart block, dizziness, headache and hypotension.

Information provided relates to Adenocor[®] manufactured by Sanofi-Aventis.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542